Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy LivaNova stock | $66.21

Own LivaNova stock in just a few minutes.

Fact checked

LivaNova PLC is a medical devices business based in the US. LivaNova shares (LIVN) are listed on the NASDAQ and all prices are listed in US Dollars. LivaNova employs 4,000 staff and has a trailing 12-month revenue of around USD$952.3 million.

How to buy shares in LivaNova

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for LivaNova. Find the stock by name or ticker symbol: LIVN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until LivaNova reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$66.21, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of LivaNova, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of LivaNova. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

LivaNova share price

Use our graph to track the performance of LIVN stocks over time.

LivaNova shares at a glance

Information last updated 2020-12-28.
Latest market closeUSD$66.21
52-week rangeUSD$33.4 - USD$80.75
50-day moving average USD$57.6124
200-day moving average USD$51.1759
Wall St. target priceUSD$72.43
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-5.41

Buy LivaNova shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy LivaNova stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

LivaNova price performance over time

Historical closes compared with the close of $66.21 from 2020-12-31

1 week (2021-01-13) -1.62%
1 month (2020-12-23) -1.81%
3 months (2020-10-20) 23.30%
6 months (2020-07-20) 22.41%
1 year (2020-01-19) N/A
2 years (2019-01-19) N/A
3 years (2018-01-19) 83.81
5 years (2016-01-20) 23.80%

Is LivaNova under- or over-valued?

Valuing LivaNova stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LivaNova's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

LivaNova's PEG ratio

LivaNova's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.0239. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into LivaNova's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

LivaNova's EBITDA

LivaNova's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$18.4 million.

The EBITDA is a measure of a LivaNova's overall financial performance and is widely used to measure a its profitability.

LivaNova financials

Revenue TTM USD$952.3 million
Gross profit TTM USD$731.6 million
Return on assets TTM -0.81%
Return on equity TTM -14.59%
Profit margin -21.89%
Book value $27.796
Market capitalisation USD$3.3 billion

TTM: trailing 12 months

Shorting LivaNova shares

There are currently 3.4 million LivaNova shares held short by investors – that's known as LivaNova's "short interest". This figure is 28.1% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting LivaNova shares can be evaluated.

LivaNova's "short interest ratio" (SIR)

LivaNova's "short interest ratio" (SIR) is the quantity of LivaNova shares currently shorted divided by the average quantity of LivaNova shares traded daily (recently around 499653.33333333). LivaNova's SIR currently stands at 6.9. In other words for every 100,000 LivaNova shares traded daily on the market, roughly 6900 shares are currently held short.

However LivaNova's short interest can also be evaluated against the total number of LivaNova shares, or, against the total number of tradable LivaNova shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case LivaNova's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 LivaNova shares in existence, roughly 70 shares are currently held short) or 0.0813% of the tradable shares (for every 100,000 tradable LivaNova shares, roughly 81 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against LivaNova.

Find out more about how you can short LivaNova stock.

LivaNova share dividends

We're not expecting LivaNova to pay a dividend over the next 12 months.

LivaNova share price volatility

Over the last 12 months, LivaNova's shares have ranged in value from as little as $33.4 up to $80.75. A popular way to gauge a stock's volatility is its "beta".

LIVN.US volatility(beta: 0.75)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LivaNova's is 0.7454. This would suggest that LivaNova's shares are less volatile than average (for this exchange).

LivaNova overview

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site